HealthMed Services, Ltd. to Expand Portfolio of Products Beyond Organ Transplantation

   HealthMed Services, Ltd. (PINKSHEETS: HEME) -- Dr. Henry J. Smith, President of HealthMed Services, Ltd., stated today that "Our business plan is to expand our portfolio of products beyond organ transplantation, to include promising new technologies that can be commercialized within a fairly short period of time."

Dr. Smith added, "In the field of Diabetes Testing the Company has developed a saliva test for monitoring glucose control in diabetes. Diabetics will be able to mail a saliva sample to a laboratory that will perform the test and record the result. Patients will be able to access their results in private using the Internet."

Dr. Smith further stated, "The acquisition and merger of Diabetes Reference Services last year gave us the enabling technologies to monitor glucose control in Type 2 diabetics in a non-invasive manner by testing saliva samples. This technology represents an important component of any diabetes prevention program. The medical profession cannot ignore that there is a diabetes epidemic occurring throughout the world and the medical and economic effects will be catastrophic if it is not recognized. However, with timely testing, counseling and simple life-style changes such as dieting and exercise, the onset of diabetes can be mitigated or prevented. The routine saliva testing under development by HealthMed Services to monitor glucose control is simple, convenient and painless, and we believe it will encourage compliance with all diabetes prevention programs."

About HealthMed Services, Ltd.

HealthMed Services, Ltd. has acquired the intellectual property rights to two important medical technologies. In the field of Organ Transplantation, the Company is developing a device for keeping isolated donor organs alive for extended periods of time outside the body. This will allow the donor organ to be transported across the country to allow better donor and patient matching. Also the better the donor organ can be preserved the better will be the outcome of the organ transplantation. In the field of Diabetes Testing, the Company has developed a saliva test for monitoring glucose control in diabetes. Diabetics will be able to mail a saliva sample to a laboratory that will perform the test and record the result. Patients will be able to access their results in private using the Internet.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with cleaning fluid and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report, quarterly reports or current reports filed from time-to-time with OTC Markets, Inc.

Contact: Richard E. Floegel [phone]